Popular Articles

Putting The Patient In Control Next Stage In Personal Healthcare Budgets Announced, UK
Patients are a step closer to getting more say over their healthcare services as plans for a national pilot project reach the next stage, the Department of Health announced.
generic viagra online
Cephalon Provides Clinical Update On Lestaurtinib In Relapsed Acute Myelogenous Leukemia
Cephalon, Inc. (Nasdaq: CEPH) announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit of lestaurtinib in this patient population when given in sequence with standard induction chemotherapy compared to those treated with standard induction chemotherapy alone. An analysis of the study showed that patients who were treated with lestaurtinib showed similar rates of complete response but no increased benefit in overall survival, compared to those who received induction chemotherapy alone.
News of the day
Cincinnati Enquirer Looks At Effects Of Antiretrovirals On The Lives Of People With HIV, Larger Epidemic
The Cincinnati Enquirer examined how the "success stories" of people living longer with HIV - such as that of former National Basketball Association player Earvin "Magic" Johnson - can "illustrate how well anti-HIV medications work and might be part of the reason the epidemic still rages." The article discussed the efficacy of antiretrovirals, their side effects and the consequences of not taking the medications (O"Farrell [1], Cincinnati Enquirer, 6/5). The Enquirer also featured an overview of the history and science of HIV (O"Farrell [2], Cincinnati Enquirer, 6/5).
Mental Health

Frankenman International Ltd Secures FDA Clearance For Its Entire CHEX Range Of Surgical Staplers

Frankenman International Ltd, the manufacturer and supplier of surgical instruments, announced that its entire CHEX™ range of surgical staplers had been granted FDA approval. This development complements the CE and ISO accreditation it has already acquired. FDA approval endorses Frankenman"s commitment to total quality in surgical stapling and wound closure devices, and further validates its position as a trusted alternative supplier in these markets. Having established itself in Europe and many other international markets, Frankenman International Ltd now plans to expand marketing of the CHEX range into Japan, Australia and Korea by the end of 2009. This will enable more patients and hospitals around the world to benefit from its cost-effective range of surgical instruments. "We are delighted to have secured FDA registration as this globally recognised quality mark will further strengthen surgeons" confidence in our CHEX range of surgical staplers and establish Frankenman International as a credible player," comments Lee Edwards, President of International Business at Frankenman International Ltd. "With a well established, professional and successful distribution network in place, we are now concentrating on strategic growth by accelerating our internal and external R & D programmes so that we can bring even more innovative instruments to our customers in the coming years." Frankenman International Ltd.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):